Skip to content

Gechai decoction for antipyretic effect and safety evaluation of COVID-19

Gechai decoction for antipyretic effect and safety evaluation of COVID-19

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300067773
Enrollment
Unknown
Registered
2023-01-21
Start date
2023-01-21
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19

Interventions

Gechai Tangfang Group:Take Gechai Tangfang
Western medicine group:Take Tylenol

Sponsors

Hangzhou TCM Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with mild and ordinary types who are infected by the new coronavirus; 2. Symptoms include no sweat, fever, chills, nasal congestion, runny nose, sore throat, itchy throat, headache, body pain, nausea, vomiting and other three yang combinations; 3. Body temperature >= 38.5 °C; 4. Age 18-75 years old, gender is not limited; 5. Within 48 hours of onset; 6. Western medicines, proprietary Chinese medicines, and traditional Chinese medicines that have not been used after the onset of the disease; 7. No cognitive impairment, able to understand and communicate correctly; 8. Those who sign the informed consent form, cooperate with the treatment, and can adhere to the completion of all treatment as planned.

Exclusion criteria

Exclusion criteria: 1. Hyperthermic convulsants; 2. Patients with serious primary diseases such as heart, liver, kidney and hematopoietic system, psychopaths; 3. Those who are allergic to the drug ingredients in this clinical trial; 4. Pregnant and lactating women; 5. Those who insist on taking medication, change drugs halfway or have incomplete information.

Design outcomes

Primary

MeasureTime frame
Time to onset of defervescence;Body temperature after the drug;

Secondary

MeasureTime frame
Number of doses;Daily morning body temperature;Daily morning heart rate;Daily morning breathing rate;Daily morning oxygen saturation;Heat syndrome;Cold syndrome;Sweat syndrome;Head and body syndrome;Urination conditions;Stool conditions;Taste situation;Stomach condition;Cough and phlegm;Symptoms of palpitation and chest tightness;Symptoms of pharynx nose and mouth;Drinking;Sleep conditions;Adverse reactions: flushing of the complexion;Adverse effects: edema;Adverse reactions: body erythema;Adverse reactions: burning sensation;Adverse effects: nausea and vomiting;Adverse effects: abdominal pain and diarrhea;Cure rate;Excellent effect rate;Effectual rate;Ineffectual rate;

Countries

China

Contacts

Public ContactJiang Liyuan

Hangzhou TCM Hospital

jiangliyuan520j@163.com+86 130 1897 6755

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026